NASDAQ$ATAI
AtaiBeckley Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Atai Life Sciences reported financial results for Q4 2023, including a net loss attributable to shareholders of $18.3 million and R&D expenses of $14.2 million.
Atai Life Sciences reported Q4 2023 financial results, highlighting a net loss of $18.3 million and R&D expenses of $14.2 million. The company is focused on developing psychedelic-based therapies for mental health disorders and anticipates several clinical milestones in the coming year.
- Strategic investment made in Beckley Psytech to advance psychedelic-based therapies.
- Phase 2a open-label results for BPL-003 (intranasal 5-MeO-DMT) showed rapid and durable antidepressant effects.
- Dosing commenced in Phase 1b study for VLS-01 (oral transmucosal DMT) with an optimized formulation.
- Cash, marketable securities, and committed term loan funding are expected to fund operations into 2026.
Headline financials
Revenue & EPS history
Atai · Revenue · Quarterly
$18K
Forward guidance
Atai anticipates several important milestones throughout the next year, including the Phase 2b readout from BPL-003.
Tailwinds
- Top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024
- Data from a Phase 2a open-label study in Alcohol Use Disorder patients is expected mid-2024.
- Initial results from the ELE-01 Phase 1/2a study are anticipated in H1 2024.
- Pivotal Trial 1 (COMP005) top-line data is expected in the fourth quarter of 2024
- A Phase 1/2a study of IBX-210 for the treatment of OUD is anticipated to initiate in the second half of this year.
Headwinds
- High degree of inter-individual PK variability and significant QT prolongation were noted across all doses for IBX-210
- Both factors have the potential to increase site burden and limit scalability.
- The ongoing Phase 2b study will evaluate 20mg and 40mg of RL-007 vs. placebo in patients living with CIAS. Topline results are expected mid-2025.
- Pivotal Trial 2 (COMP006) top-line data is anticipated mid-2025.
- Phase 2 open-label efficacy data in PTSD is expected in Spring 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+0.7%
Avg return
Earnings day
+3.3%
Avg return
5 days after
+2.2%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+15.1%
Q4 2022
Best reaction
-17.7%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | -0.5% | — | |
| Q4 2026 | -1.1% | +14.7% | +7.1% | |
| Q3 2025 | -2.0% | -10.6% | -3.2% | |
| Q2 2025 | -1.2% | -2.0% | +14.3% | |
| Q1 2025 | +1.4% | +30.5% | +49.6% | |
| Q4 2024 | -1.4% | -2.0% | -4.1% | |
| Q3 2024 | -6.2% | +14.4% | -6.8% | |
| Q2 2024 | -5.6% | -1.6% | -0.8% | |
| Q1 2024 | -2.6% | -9.4% | -28.3% | |
| Q4 2023 | +3.9% | +4.5% | +7.8% | |
| Q3 2023 | +4.3% | -3.5% | +11.3% | |
| Q2 2023 | -4.5% | -8.5% | -18.8% | |
| Q1 2023 | -5.0% | -3.0% | -12.5% | |
| Q4 2022 | +15.1% | +33.6% | +82.4% | |
| Q3 2022 | +1.1% | +5.9% | +17.6% | |
| Q2 2022 | +4.1% | -1.3% | -12.7% | |
| Q1 2022 | +13.2% | +9.9% | -9.1% | |
| Q4 2021 | -6.1% | -2.0% | -20.8% | |
| Q3 2021 | -17.7% | -21.9% | -54.3% | |
| Q1 2021 | +10.2% | +13.1% | +12.7% | |
| Q2 2021 | +13.0% | +9.0% | +11.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro